Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-21 in Stage III Melanoma
NCT00601861Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Feb 2008
- Primary completion
- Jun 2008
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human interleukin 21 in Malignant Melanoma (MM), sponsored by Novo Nordisk. Primary endpoint: Complete pathological response rate in the lymph nodes at 4 weeks. Started Feb 2008; status: terminated.
02
Drugs
recombinant human interleukin 21
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00601861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601861.